ACRV
Acrivon Therapeutics, Inc.
2.20$
+7.0%
vs. previous close
Closing price · As of: Sep 22, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 78.7% | 94.2% | 72.9% | 93.8% | 92.4% | 92.9% | |
| 72.4% | 93.4% | 16.3% | 26.0% | 20.3% | 32.0% | |
| 72.4% | 93.4% | 70.5% | 92.2% | 91.3% | 91.4% | |
| 2.7% | 5.4% | 1.2% | – | – | – | |
| 485.0% | 122.3% | 5.9% | 12.3% | 10.1% | 13.3% | |
| 28.1% | 2.7% | 3.6% | 9.6% | 8.8% | 12.1% | |
| 2.7% | 0.6% | 0.4% | 0.6% | 0.5% | 0.9% | |
| 6.2% | 0.9% | 0.5% | 3.7% | 0.4% | 1.8% | |
| -385.0% | -22.3% | 94.1% | 87.7% | 89.9% | 86.7% | |
| -394.6% | -23.3% | -30.9% | -84.2% | -100.2% | -211.9% | |
| 590.8% | 12.1% | 12.1% | 16.0% | 19.5% | 29.7% |
Data as of: September 22, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.